1164 results for 'erbb2 her'
-
The EGFR/HER Family: Dimerisation, Ligand Independence & Resistance(Page)
Phosphatases and PTP1B – Mini review(Post)
IntroductionThe human kinome is estimated to contain 518 genes, in comparison to the estimated 180 genes that comprise the phosphatome (Arena et al., 2005). These kinase genes represent a signif
Advantages of Small Molecule Inhibitors in Therapeutic Interventions(Post)Small molecule inhibitors represent a significant advancement in the field of therapeutic interventions, offering a versatile approach to treating a myriad of diseases, including cancer, viral inf
Personalized Vaccines in Cancer Treatment: The Future of Immunotherapy(Post)What Are Personalized Cancer Vaccines? Personalized cancer vaccines are a cutting-edge approach in cancer treatment that are designed to activate a patient's immune sy
Obinutuzumab: Advancing Targeted Therapy in Hematologic Cancers(Post)Quick Facts About ObinutuzumabWhat is Obinutuzumab?Obinutuzumab is a monoclonal antibody targeting CD20, primarily used in treating B-cell malignancies such as chronic lymphocytic leukem
Targeting Immune Checkpoints as Cancer Therapy(Post)In recent years, the field of oncology has witnessed a paradigm shift with the advent of immunotherapy, a treatment modality that harnesses the body's immune system to combat cancer. Among the mos
Indatuximab: Advancing CD138-Targeted Therapy in Cancer Research(Post)What You Need to Know About IndatuximabWhat is Indatuximab?Indatuximab ravtansine is an experimental monoclonal antibody-drug conjugate (ADC) that targets CD138, a protein highly express
Belantamab: A Game-Changer in Multiple Myeloma Therapy(Post)Quick Facts About BelantamabWhat is Belantamab?Belantamab Mafodotin is a cutting-edge antibody-drug conjugate (ADC) designed for the treatment of relapsed or refractory multiple myeloma.
Tocilizumab: Advancing Therapeutics and Research with Biosimilars(Post)What You Need to Know About TocilizumabWhat is Tocilizumab?Tocilizumab is a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, widely used for managing autoimmune and in
Pinatuzumab: Advancing Cancer Research and Therapeutics(Post)Quick Facts About PinatuzumabWhat is Pinatuzumab?Pinatuzumab is an antibody-drug conjugate (ADC) designed to target CD22, a protein highly expressed on B-cell malignancies, including non
Gemtuzumab: Advancing CD33-Targeted Therapies in AML Research(Post)Key Facts About GemtuzumabWhat is Gemtuzumab?Gemtuzumab is an antibody-drug conjugate (ADC) targeting CD33, a protein expressed on the surface of myeloid cells. It is widely recognized f
Enavatuzumab: Revolutionizing Cancer Research Through Novel Therapeutics(Post)Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibody targeting the TWEAK receptor (Fn14), pivotal in tumor growth and immune regulation.What is the me
Macrophage Activation: A Keystone in Immune Response and Therapeutic Potential(Post)In the intricate tapestry of the immune system, macrophages play a pivotal role, orchestrating a wide range of biological responses that protect the body against pathogens, remove cellular debris,
EGF Family (Post)Epidermal Growth Factor (EGF) is a protein that stimulates cell growth and differentiation by binding to its receptor epidermal growth factor receptor (EGFR) which triggers ligand-induced d
Zilovertamab: Unlocking the Potential of ROR1-Targeted Therapy(Post)Quick Facts About ZilovertamabWhat is Zilovertamab?Zilovertamab is a monoclonal antibody targeting ROR1, a receptor tyrosine kinase overexpressed in hematologic cancers and solid tumors.
Lemzoparlimab: Targeting CD47 for Cancer Immunotherapy Advancements(Post)Quick Facts About LemzoparlimabWhat is Lemzoparlimab?Lemzoparlimab is a monoclonal antibody that targets CD47, a protein known for its role in helping tumors evade the immune system. By
Sirexatamab: Advancing CD47-Targeted Cancer Therapy and Research(Post)Quick Facts About SirexatamabWhat is Sirexatamab?Sirexatamab is an investigational monoclonal antibody designed to target CD47, a key immune checkpoint involved in cancer evasion.How Doe
Lirilumab: Unlocking the Potential of Anti-KIR Therapy in Cancer Research(Post)Quick Facts About LirilumabWhat is Lirilumab?Lirilumab is an anti-KIR monoclonal antibody designed to enhance natural killer (NK) cell activity by blocking killer-cell immunoglobulin-lik
Monalizumab: A Breakthrough in Cancer Immunotherapy Targeting NKG2A(Post)Quick Facts About MonalizumabWhat is Monalizumab?Monalizumab is a first-in-class immune checkpoint inhibitor targeting NKG2A, developed to enhance anti-tumor immune response by blocking
Cancer Metabolism: Tumorigenesis, Metabolic Therapy & The Warburg Effect(Post)Cancer Metabolism is the mechanism by which cancer cells make energy in order for them to grow and spread. Even in the presence of oxygen, cancer cells increase glucose uptake and produce lactate,
Featured
Human CAT (Catalase) ELISA Kit (HUFI07676)
Human MICA ELISA Kit (HUFI00015)
Fatty Acid Oxidation (FAO) Assay Kit (BR00001)
Anti-Mouse IFNAR-1 In Vivo Antibody - Low Endotoxin (IVMB0202)
Anti-Mouse CD25 In Vivo Antibody - Low Endotoxin (IVMB0148)
Anti-Mouse NK1.1 In Vivo Antibody - Low Endotoxin (IVMB0100)
Anti-Mouse PD-1 Antibody [RMP1-14] In Vivo-Low Endotoxin (IVMB0037)
LSAMP Rabbit Polyclonal Antibody (CAB14248)
MCM4 Rabbit Polyclonal Antibody (CAB13513)
VEGF Rabbit Polyclonal Antibody (CAB12303)
MDA ELISA Kit (UNFI0048)
Dopamine ELISA Kit (UNFI0013)
Serotonin ELISA Kit (UNFI0018)
PGE2 ELISA Kit (UNFI0032)
Human IL-6 ELISA Kit (HUFI00180)